Latest:
Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer
Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Komal L. Jhaveri, MD, FACP
Latest:
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Kosj Yamoah, MD
Latest:
Dr. Yamoah on Racial Disparities in Prostate Cancer
Kosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.
Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center
Latest:
Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma
Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.
Krisha J. Howell, MD
Latest:
Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma
Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.
Krishna Komanduri, MD
Latest:
TIL Therapy: Lessons Learned and Potential Future Directions in Care
Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.
Krishna Vanaja Donkena, PhD
Latest:
Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer
Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.